Τίτλος:
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Importance: A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to systematically evaluate the effect of DMDs on disability progression in RRMS Methods: We performed a systematic review on MEDLINE and SCOPUS databases to include all available placebo-controlled randomized clinical trials (RCTs) of RRMS patients that reported absolute numbers or percentages of disability progression during each study period. Observational studies, case series, case reports, RCTs without placebo subgroups and studies reporting the use of RRMS therapies that are not still officially approved were excluded. Risk ratios (RRs) were calculated in each study protocol to express the comparison of disability progression in RRMS patients treated with a DMD and those RRMS patients receiving placebo. The mixed-effects model was used to calculate both the pooled point estimate in each subgroup and the overall estimates. Results: DMDs for RRMS were found to have a significantly lower risk of disability progression compared to placebo (RR = 0.72, 95%CI: 0.66-0.79; p < 0.001), with no evidence of heterogeneity or publication bias. In subsequent subgroup analyses, neither dichotomization of DMDs as "first" and "second" line RRMS therapies [(RR = 0.72, 95% CI = 0.65-0.80) vs. (RR = 0.72, 95% = 0.57-0.91); p = 0.96] nor the route of administration (injectable or oral) [RR = 0.75 (95% CI = 0.64-0.87) vs. RR = 0.74 (95% CI = 0.66-0.83); p = 0.92] had a differential effect on the risk of disability progression. Either considerable (5-20%) or significant (>20%) rates of loss to follow-up were reported in many study protocols, while financial and/ or other support from pharmaceutical industries with a clear conflict of interest on the study outcomes was documented in all included studies. Conclusions: Available DMD are effective in reducing disability progression in patients with RRMS, independently of the route of administration and their classification as "first" or "second" line therapies. Attrition bias needs to be taken into account in the interpretation of these findings. © 2015 Tsivgoulis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Συγγραφείς:
Tsivgoulis, G.
Katsanos, A.H.
Grigoriadis, N.
Hadjigeorgiou, G.M.
Heliopoulos, I.
Papathanasopoulos, P.
Kilidireas, C.
Voumvourakis, K.
Dardiotis, E.
Helani (Hellenic Academy Of Neuroimmunology)
Εκδότης:
Public Library of Science
Λέξεις-κλειδιά:
beta1a interferon; fingolimod; fumaric acid dimethyl ester; glatiramer; interferon beta serine; natalizumab; peginterferon beta1a; teriflunomide; immunosuppressive agent, Article; disease course; drug efficacy; drug response; human; meta analysis; multiple sclerosis; outcome assessment; primary health care; randomized controlled trial (topic); risk assessment; systematic review; Multiple Sclerosis, Relapsing-Remitting; treatment outcome, Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Treatment Outcome
DOI:
10.1371/journal.pone.0144538
